Dr Pearly Khaw is currently the lead Radiation Oncologist in Gynae-Oncology at the Peter MacCallum Cancer Centre. She has been involved in the clinical management of women with Gynaecological cancers since 2005.
She is also a clinical researcher and is actively involved in ANZGOG, the leading Clinical Trials Group for Australia and New Zealand. She is currently a Board Director and Chair of the Quality Assurance Committee with ANZGOG, as well as a member of the Research Advisory Committee and the Uterine Tumour Type Working Group. She led the Radiation Oncology Quality Assurance Program of the PORTEC-3 trial in Australia & NZ, through the Trans-Tasman Radiation Oncology Group (TROG), in conjunction with ANZGOG. She is currently the Radiation Oncology lead involved in the development of a number of new trials at ANZGOG.
Dr Khaw has also led the formation of the Radiation Oncology subspecialty group within both ANZGOG and through RANZCR, in an effort to raise the profile of this craft group. She pioneered the Radiation Oncology Workshop at the ANZGOG ASM and has continued to facilitate this event with Dr Viet Do, providing others with an opportunity to learn about the art of Radiation Oncology in the management of Gynae malignancies.
In addition to this, Dr Khaw is a member of the Cancer Council of Victoria’s Council and the Medical and Scientific Committee, as well as participating in the Gynaecological Cancer Optimum Care pathways for Endometrial and Cervical Cancer. She has recently completed her term as a member of Cancer Australia’s National Gynaecological Cancer Advisory Group where she was involved in a number of projects to improve quality of care for women in Australia with Gynaecological Cancer. She has also been involved with the development and updating of the Radiation Oncology EviQ Guidelines in Gynaecological Cancer.
Internationally, Dr Khaw is a member of IGCS, ESGO, and ESTRO. Through ANZGOG she also participates in GCIG where she has the opportunity to be involved in discussion regarding development of new International Trials in Endometrial Cancer. She is a current reviewer for the International Journal of Gynecological Cancer, as well as for the Journal of Medical Imaging and Radiation Oncology.
Dr Khaw is committed to improving outcomes for all women with Gynaecological Cancers
NHMRC Project Grant 2008: “Randomized Phase 3 Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Cancer: PORTEC 3 (Intergroup Trial).” (CIC)
$443,125 over 3 years commencing 2009
Cancer Australia Project Grant 2012: “Randomized Phase 3 Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Cancer: PORTEC 3 (Intergroup Trial).” (CIC)
$300,778 over 3 years commencing 2013
NHMRC Project Grant 2014: “A randomised trial of lymphadenectomy to direct adjuvant therapy in high risk endometrial cancer: The STATEC trial.” (CIF)
$1.27 mil over 5 years commencing 2015
NHMRC Project Grant 2015: “Reducing the Greatest Uncertainty in Radiotherapy.” (AI)
$594,197 over 3 years commencing 2016